We have been fortunate to complete two financings in recent months. We believe that these two financings together have provided enough capital to support TTX-MC138's Phase I clinical trial and company ...

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Friday. Separately, HC Wainwright ...

"We are honored to welcome Dr. Zamore to our Science Advisory Board," said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. "His deep expertise in RNA biology ...

BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today ...

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.